(CercleFinance.com) – Novacyt lost ground again this Thursday on the Paris Stock Exchange after the presentation of its results for the 2021 financial year and an update on its growth strategy.
The diagnostics specialist’s turnover was £95.8m last year, up from £277.2m in 2020.
In its press release, Novacyt specifies that this last figure does not take into account the 40.9 million pounds of turnover linked to the DHSC, which is the subject of a contractual dispute.
Revenue from Covid-19 products accounted for 86% of total revenue in 2021, compared to 95% in 2020.
Ebitda stands at 37.1 million pounds, a figure which rises to a loss of 35.7 million taking into account the exceptional items due to the commercial dispute with the DHSC, which forced the group to recognize £35.8 million exceptional charges in 2021.
Novacyt evokes annual results “in line with market expectations”, despite a testing industry against the Covid “in full change”.
From a strategic perspective, the Franco-British company says it wants to leverage its core capabilities to become a global leader in clinical diagnostics and achieve annual sales of over £100 million by five years.
A message received without much enthusiasm by investors, who sanctioned the title with a decline of 6.5% at the end of the morning, however less than the 15% drop posted at the start of the session.
The action is now down more than 58% since the start of the year.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
